Immitra Bio
Agent35Agent Readiness: 35/100. Below median. Measured by StartupHub.ai. Median 41.Trust60Data Trust: 60/100. Below median. Measured by StartupHub.ai. Median 61.Scalable, one-time curative in-vivo gene editing therapies.
About
Immitra Bio is developing a scalable, in-vivo gene editing platform designed to offer a single, off-the-shelf injection to cure rare genetic diseases. Their mission is to provide accessible, curative genetic medicine for the 400 million people worldwide affected by these conditions, addressing the limitations of current ex-vivo therapies.
Listed competitors
A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.
Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.
Also in this space
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.
Shares Biotechnology, Drug Discovery
A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
Shares Biotechnology, Genomics
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Therapeutics
A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
Shares Biotechnology, Pharmaceuticals
Key facts
- Website
- immitrabio.com
- Headquarters
- Zürich, Switzerland
- Founded
- 2024
- Total funding
- $3M (Pre-Seed)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Jul 2026 | Pre-Seed | $3M | BackBone Ventures |
Tech stack
Detected on immitrabio.com, last scanned 15 Oct 2026. Run your own scan
- Frontend
- Bootstrap
- CDN
- Fastly
- Email provider
- Microsoft 365
Immitra Bio scores 9. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Immitra Bio trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Immitra Bio is 60 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Immitra Bio raised?
Immitra Bio has raised a total of $3M in funding. The most recent round on record is Pre-Seed.
